927 Shares in Becton, Dickinson and Company (NYSE:BDX) Bought by Barlow Wealth Partners Inc.

Barlow Wealth Partners Inc. bought a new position in shares of Becton, Dickinson and Company (NYSE:BDX) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 927 shares of the medical instruments supplier’s stock, valued at approximately $226,000.

A number of other institutional investors have also added to or reduced their stakes in the business. OFI Invest Asset Management bought a new stake in Becton, Dickinson and Company during the third quarter valued at approximately $25,000. DiNuzzo Private Wealth Inc. bought a new position in Becton, Dickinson and Company in the fourth quarter valued at $30,000. Fortitude Family Office LLC bought a new stake in Becton, Dickinson and Company during the fourth quarter worth about $35,000. Venturi Wealth Management LLC increased its position in shares of Becton, Dickinson and Company by 552.0% during the 4th quarter. Venturi Wealth Management LLC now owns 163 shares of the medical instruments supplier’s stock valued at $40,000 after purchasing an additional 138 shares during the last quarter. Finally, Arlington Trust Co LLC bought a new stake in Becton, Dickinson and Company in the 4th quarter worth approximately $41,000. 86.97% of the stock is currently owned by institutional investors.

Becton, Dickinson and Company Trading Up 0.2 %

BDX stock traded up $0.56 during midday trading on Tuesday, hitting $237.14. The company had a trading volume of 1,120,070 shares, compared to its average volume of 1,408,706. The company has a current ratio of 1.41, a quick ratio of 0.97 and a debt-to-equity ratio of 0.62. Becton, Dickinson and Company has a 52 week low of $229.40 and a 52 week high of $287.32. The stock has a market cap of $68.54 billion, a price-to-earnings ratio of 52.23, a PEG ratio of 1.92 and a beta of 0.45. The stock’s 50 day moving average price is $238.27 and its 200 day moving average price is $239.97.

Becton, Dickinson and Company (NYSE:BDX) last posted its earnings results on Thursday, May 2nd. The medical instruments supplier reported $3.17 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.97 by $0.20. The company had revenue of $5.05 billion for the quarter, compared to analysts’ expectations of $5.04 billion. Becton, Dickinson and Company had a return on equity of 13.90% and a net margin of 6.76%. Becton, Dickinson and Company’s quarterly revenue was up 4.6% on a year-over-year basis. During the same period last year, the firm earned $2.86 earnings per share. As a group, equities research analysts expect that Becton, Dickinson and Company will post 13.04 earnings per share for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, June 28th. Stockholders of record on Monday, June 10th will be given a $0.95 dividend. The ex-dividend date is Monday, June 10th. This represents a $3.80 annualized dividend and a dividend yield of 1.60%. Becton, Dickinson and Company’s dividend payout ratio is 83.70%.

Insider Activity

In other Becton, Dickinson and Company news, SVP Thomas J. Spoerel sold 282 shares of the firm’s stock in a transaction dated Thursday, March 14th. The shares were sold at an average price of $238.29, for a total value of $67,197.78. Following the completion of the sale, the senior vice president now directly owns 2,276 shares in the company, valued at $542,348.04. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other news, EVP Michael David Garrison sold 1,715 shares of Becton, Dickinson and Company stock in a transaction that occurred on Tuesday, April 30th. The shares were sold at an average price of $232.81, for a total transaction of $399,269.15. Following the completion of the transaction, the executive vice president now directly owns 5,381 shares in the company, valued at $1,252,750.61. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Thomas J. Spoerel sold 282 shares of the business’s stock in a transaction that occurred on Thursday, March 14th. The stock was sold at an average price of $238.29, for a total value of $67,197.78. Following the completion of the sale, the senior vice president now directly owns 2,276 shares in the company, valued at $542,348.04. The disclosure for this sale can be found here. Insiders own 0.31% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Barclays lifted their price target on shares of Becton, Dickinson and Company from $305.00 to $312.00 and gave the stock an “overweight” rating in a research note on Monday. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, Becton, Dickinson and Company presently has a consensus rating of “Moderate Buy” and an average target price of $281.40.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.